Vir(US:VIR) ZACKS·2026-02-24 02:56分组1 - Vir Biotechnology reported a quarterly loss of $0.31 per share, better than the Zacks Consensus Estimate of a loss of $0.42, and improved from a loss of $0.76 per share a year ago, resulting in an earnings surprise of +26.89% [1] - The company posted revenues of $64.07 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 243.23%, compared to year-ago revenues of $12.37 million [2] - Vir Biotechnology shares have increased by approximately 25.4% since the beginning of the year, outperforming the S&P 500's gain of 0.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.60 on revenues of $2.41 million, and for the current fiscal year, it is -$2.94 on revenues of $13.28 million [7] - The Medical - Biomedical and Genetics industry, to which Vir Biotechnology belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]